NCT00635154 · OUTCOME

Number of Patients With Response to Treatment With Dexamethasone and Anakinra

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma · Source last updated 2018-06-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: During Active treatment (up to 5 years)

What was measured

Response on 2 consecutive months during active treatment with anakinra alone or in combination with dexamethasone. Response criteria is the same as in Primary Outcome Measure.

Analysis population: Only participants who received Anakinra with dexamethasone were analyzed.

Groups in this outcome

Anakinra With Dexamethasone

Patients in this outcome received both Anakinra (100mg daily subcutaneously administered) and dexamethasone (either 20mg/week OR 40mg days 1-4, 9-12, 17-20 every 28 days during odd cycles OR 40 mg days 1-4 every 28 days during even cycles)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Anakinra With Dexamethasone	29

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Anakinra With Dexamethasone	14	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
14

denoms

counts
group Id
OG000
value
29
units
Participants

description

Response on 2 consecutive months during active treatment with anakinra alone or in combination with dexamethasone. Response criteria is the same as in Primary Outcome Measure.

groups

description
Patients in this outcome received both Anakinra (100mg daily subcutaneously administered) and dexamethasone (either 20mg/week OR 40mg days 1-4, 9-12, 17-20 every 28 days during odd cycles OR 40 mg days 1-4 every 28 days during even cycles)
id
OG000
title
Anakinra With Dexamethasone

param Type

NUMBER

population Description

Only participants who received Anakinra with dexamethasone were analyzed.

reporting Status

POSTED

time Frame

During Active treatment (up to 5 years)

title

Number of Patients With Response to Treatment With Dexamethasone and Anakinra

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice